EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?

Double antiplatelet therapy, which includes aspirin and platelet P2Y12 receptor inhibitors (hereinafter P2Y12 inhibitor) is the main component of treatment and secondary prevention after ACS. In recent years, the issue of determining whether it is expedient for P2Y12 inhibitors to be early prescribe...

Full description

Saved in:
Bibliographic Details
Main Author: Roman M. Shakhnovich
Format: Article
Language:Russian
Published: «REMEDIUM GROUP» Ltd. 2018-12-01
Series:Атеротромбоз
Subjects:
Online Access:https://www.aterotromboz.ru/jour/article/view/168
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850182207855919104
author Roman M. Shakhnovich
author_facet Roman M. Shakhnovich
author_sort Roman M. Shakhnovich
collection DOAJ
description Double antiplatelet therapy, which includes aspirin and platelet P2Y12 receptor inhibitors (hereinafter P2Y12 inhibitor) is the main component of treatment and secondary prevention after ACS. In recent years, the issue of determining whether it is expedient for P2Y12 inhibitors to be early prescribed to patients with ACS – prior to coronary angiography, when coronary anatomy is unknown – has been widely debated. The review provides comprehensive up-to-date information on this topic based on data from randomized trials, registers, and official clinical guidelines.
format Article
id doaj-art-3d653318ec744cf6a70416306ca51368
institution OA Journals
issn 2307-1109
2658-5952
language Russian
publishDate 2018-12-01
publisher «REMEDIUM GROUP» Ltd.
record_format Article
series Атеротромбоз
spelling doaj-art-3d653318ec744cf6a70416306ca513682025-08-20T02:17:41Zrus«REMEDIUM GROUP» Ltd.Атеротромбоз2307-11092658-59522018-12-0102768610.21518/2307-1109-2018-2-76-86148EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?Roman M. Shakhnovich0National Medical Research Centre of Cardiology, Federal State Budgetary Institution of the Ministry of Health of the Russian FederationDouble antiplatelet therapy, which includes aspirin and platelet P2Y12 receptor inhibitors (hereinafter P2Y12 inhibitor) is the main component of treatment and secondary prevention after ACS. In recent years, the issue of determining whether it is expedient for P2Y12 inhibitors to be early prescribed to patients with ACS – prior to coronary angiography, when coronary anatomy is unknown – has been widely debated. The review provides comprehensive up-to-date information on this topic based on data from randomized trials, registers, and official clinical guidelines.https://www.aterotromboz.ru/jour/article/view/168acutecoronary syndromeplatelet p2y12 receptor inhibitorsclopidogrelticagrelorprasugrel
spellingShingle Roman M. Shakhnovich
EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?
Атеротромбоз
acutecoronary syndrome
platelet p2y12 receptor inhibitors
clopidogrel
ticagrelor
prasugrel
title EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?
title_full EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?
title_fullStr EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?
title_full_unstemmed EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?
title_short EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?
title_sort early prescription of platelet p2y12 receptor inhibitors to patients with acute coronary syndrome a benefit or a harm
topic acutecoronary syndrome
platelet p2y12 receptor inhibitors
clopidogrel
ticagrelor
prasugrel
url https://www.aterotromboz.ru/jour/article/view/168
work_keys_str_mv AT romanmshakhnovich earlyprescriptionofplateletp2y12receptorinhibitorstopatientswithacutecoronarysyndromeabenefitoraharm